BRAF gene mutation testing is now considered critical in diagnosis, prognosis, treatment, and predicting patient outcome in response to targeted therapy for multiple cancer types. Mutations in BRAF have been reported in up to 60% of cutaneous...
Read More ›NSCLC accounts for about 85% of lung cancers and includes predominantly adenocarcinomas and squamous cell carcinomas. In the United States, about 15% of patients with NSCLC have mutations in Epidermal Growth Factor Recepter (EGFR). Testing for EGFR...
Read More ›Colorectal cancer (CRC) remains the third leading cause of cancer-related deaths in the United States and nearly 50% of patients will experience metastases during their lives. Anti EGFR targeted therapy is used for treatment of metastatic colorectal...
Read More ›Test code: L186 The spectrum of abnormalities in serum immunoglobulin concentrations is broad. Abnormal concentrations range from a virtual absence of one or more of the three major classes of immunoglobulin (IgG, IgA and IgM) to polyclonal...
Read More ›